318 related articles for article (PubMed ID: 19737998)
21. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
[TBL] [Abstract][Full Text] [Related]
24. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
27. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
28. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
29. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
Sun JM; Ahn JS; Jung SH; Sun J; Ha SY; Han J; Park K; Ahn MJ
J Clin Oncol; 2015 Aug; 33(22):2450-6. PubMed ID: 26124486
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
[TBL] [Abstract][Full Text] [Related]
32. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
34. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
Mubarak N; Gaafar R; Shehata S; Hashem T; Abigeres D; Azim HA; El-Husseiny G; Al-Husaini H; Liu Z
BMC Cancer; 2012 Sep; 12():423. PubMed ID: 23006447
[TBL] [Abstract][Full Text] [Related]
35. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
36. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
37. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
38. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
39. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
40. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]